✦ LIBER ✦

Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair

✍ Scribed by Zhornitsky, Simon; Wee Yong, Voon; Koch, Marcus W.; Mackie, Aaron; Potvin, Stéphane; Patten, Scott B.; Metz, Luanne M.

Book ID: 120667617
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 111 KB
Category: Article
ISSN: 1755-5930
DOI: 10.1111/cns.12154

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dimethyl fumarate (BG-12) for the treatm

Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis

✍ Stangel, Martin; Linker, Ralf A 📂 Article 📅 2013 🏛 Expert Reviews 🌐 English ⚖ 927 KB

Prodrugs of fumarate esters for the trea

Prodrugs of fumarate esters for the treatment of psoriasis and multiple sclerosis—a computational approach

✍ Rafik Karaman, Ghadeer Dokmak, Maryam Bader, Hussein Hallak, Mustafa Khamis, Lau 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 634 KB

The Cost Effectiveness of BG-12 (Dimethy

The Cost Effectiveness of BG-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

✍ Su, W.; Walker, A.; Sarda, S.; Kansal, A.R.; Vicente, C.; Deniz, B. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Oral fumaric acid esters for the treatme

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

✍ S. Schimrigk; N. Brune; K. Hellwig; C. Lukas; B. Bellenberg; M. Rieks; V. Hoffma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

Oral fumaric acid esters for the treatme

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

✍ S. Schimrigk; N. Brune; K. Hellwig; C. Lukas; B. Bellenberg; M. Rieks; V. Hoffma 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

An exploratory, prospective, open‐label study of fumaric acid esters (FAE, Fumaderm®) was conducted in patients with relapsing–remitting multiple sclerosis (RRMS). The study consisted of the following four phases: 6‐week baseline, 18‐week treatment (target dose of 720 mg/day), 4‐week washout, and a

Considerations on discontinuing natalizu

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

✍ Joseph R. Berger; Diego Centonze; Giancarlo Comi; Christian Confavreux; Gary Cut 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 3 views